Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
About this item
Full title
Author / Creator
Publisher
London: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between programmed death-1 and programmed death-ligand 1 and 2 [PD-L1/PD-L2]) as first-line therapy for advanced non-small-cell lung cancer (NSCLC). In the Phase III KEYNOTE-024 study, pembrolizumab monotherapy significantly i...
Alternative Titles
Full title
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2323461188
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2323461188
Other Identifiers
ISSN
1750-743X
E-ISSN
1750-7448
DOI
10.2217/imt-2017-0121
